Summary
This study investigates the acute haemodynamic effects of Quinapril (CI-906) a new non-sulphydryl angiotensin converting enzyme inhibitor in 15 patients with refractory congestive cardiac failure. There were 14 males and 1 female mean age 59.5 years.
After administration of Quinapril there was a significant reduction in mean arterial pressure (MAP) from 93.1 to 79 mmHg, systemic vascular resistance (SVR) from 1887 to 1349 dyn s cm−5 and PCW from 27.3 to 15.3 mmHg. This was accompanied by an increase in CO from 3.7 to 4.7 l/min, cardiac index (CI) from 1.97 to 2.5 l/min/m2 and Stroke volume index from 21.1 to 28.7 ml/m2. There was no significant change in heart rate (HR), right atrial pressure (RAP), or pulmonary vascular resistance.
The peak effect on pulmonary capillary wedge pressure (PCW) and cardiac output (CO) occurred at 75–120 min after Quinapril administration. The maximum effect on mean arterial pressure (MAP) occurred slightly later at 120–150 min. SVR and CI exhibited 2 periods of peak effects, at 90 and 180 min. This time course is very similar to that observed in studies on the acute effects of Captopril.
The significant improvement in haemodynamic measurements acutely, following administration of Quinapril 5 mg orally, suggests that this drug is worthy of further study in the management of patients with refractory congestive cardiac failure, in particular its long term effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ondetti MA, Rubin B, Cushman DW (1977) Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196: 441–444
Case DB, Laragh JH (1979) Reactive hyperreninemia in renovascular hypertension after angiotensin blockade with saralasin or converting-enzyme inhibitor. Ann Intern Med 91: 153–160
Murthy VS, Waldron TL, Goldberg ME (1978) The mechanism of bradykinin potentiation after inhibition of angiotensin-converting enzyme by SQ 14225 in conscious rabbits. Circ Res 43 [Suppl 1]: 40–45
Cody RJ, Franklin KW, Kluger J, Laragh JH (1984) Sympathetic responsiveness and plasma norepinephrine during therapy of congestive heart failure with captopril. Am J Med 72: 791–797
Thibonnier M, Soto ME, Menard J, Aldiger JC, Corvol P, Milliez P (1981) Reduction of plasma and urinary vasopressin during treatment of severe hypertension by captopril. Eur J Clin Invest 11: 449–453
Atkinson AB, Robertson JIS (1979) Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 2: 836–839
Turini GA, Brunner HR, Gribic M, Waeber B, Gavras H (1979) Improvement of chronic congestive heart failure by oral captopril. Lancet 1: 1213–1215
Kramer B, Massie B, Topic N (1982) Controlled trial of captopril for heart failure: Effects on haemodynamics, scintigraphy, and exercise tolerance. Am J Cardiol 49: 925
Captopril Multicenter Research Group (1983) A placebo controlled trial of captopril in refractory chronic congestive failure. J Am Coll Cardiol 2: 755–763
Cleland JGF, Dargie HJ, Robertson JIS, Ball SG, Hodsman GP (1984) The use of captopril in the management of cardiac failure. Scott Med J 29: 129–130
Chatterjee K, Parmley WW, Massie B et al. (1976) Oral hydrallazine for chronic refractory heart failure. Circulation 54: 879–883
Franciosa JA, Pierpont G, Cohn JN (1977) Haemodynamic improvement after oral hydrallazine on left ventricular failure: A comparison with nitroprusside infusion in 16 patients. Ann Intern Med 86: 388–393
Williams DO, Bommer WJ, Miller RR et al. (1977) Haemodynamic assessment of oral peripheral vasodilator therapy in chronic congestive heart failure; prolonged effectiveness of isosorbide dinitrate. Am J Cardiol 39: 84–90
Turini GA, Waeber B, Brunner HR (1983) The renin-angiotensin system in refractory heart failure: clinical, haemodynamic and hormonal effects of captopril and enalapril. Eur Heart J 4 [Suppl A]: 189–197
Edwards CRW, Padfield PL (1985) Angiotensin-converting enzyme inhibitors: Past, present and bright future. Lancet 1: 30–34
Packer M (1985) Converting-enzyme inhibition for severe chronic heart failure: Views from a skeptic. Int J of Cardiol 7: 111–120
Levine TB, Franciosa JA, Cohn JA (1980) Acute and long-term response to an oral converting-enzyme inhibitor, Captopril, in congestive heart failure. Circulation 62: 35–41
Ader R, Chatterjee K, Ports T, Brundage B, Hiramatsu B, Parmley W (1980) Immediate and sustained haemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation 61: 931–937
Cody RJ, Covit AB, Schaer GL, Laragh JH (1983) Evaluation of a long-acting converting enzyme inhibitor (Enalapril) for the treatment of chronic congestive heart failure. J Am Coll Cardiol 1: 1154–1159
Sharpe DN, Coxon RJ, Douglas JE, Long B (1980) Low dose Captopril in chronic heart failure: Acute haemodynamic effects and long-term treatment. Lancet 2: 1154–1157
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Holt, P., Najm, J. & Sowton, E. The acute haemodynamic effects of quinapril, a new non-sulfhydryl angiotensin converting enzyme inhibitor, in patients with severe congestive cardiac failure. Eur J Clin Pharmacol 31, 9–14 (1986). https://doi.org/10.1007/BF00870978
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00870978